The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 17, 2026
Snapshot (as of Jul 17, 2026): AbbVie Inc. (ABBV) pays a $6.83 annual dividend ($1.73 quarterly), yielding 2.68% at $254.45/share. Next ex-dividend date 2026-07-15. 11+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.68%
Annual Dividend: $6.83 per share
Payout Ratio: 324.8% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2026-07-15
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 14
AbbVie Inc. is a global biopharmaceutical company built around blockbuster drugs like HUMIRA, SKYRIZI, and RINVOQ, and it pays a 2.58% dividend yield. The AbbVie Inc. dividend runs at $6.74 per share on a trailing annual basis, paid quarterly, with the next ex-dividend date on July 15, 2026. ABBV stock carries a beta of 0.283, meaning it moves far less than the broader market, which suits income investors who prioritize low volatility over high yield.
AbbVie Inc. pays out 324.8% of earnings as dividends, a payout ratio classified as high (above 75%). That figure is extreme by any measure, though the company's portfolio spans essential, recurring-demand therapies across immunology, oncology, and neurology, including products like VENCLEXTA and Botox, which generate ongoing prescription revenue. AbbVie Inc. dividend safety is the central question for income investors here: the payout ratio leaves virtually no earnings cushion, and any meaningful pressure on drug pricing or product revenue would put the dividend under strain.
Over the past 12 years, AbbVie Inc. has grown its dividend at 12.5% per year. Per-share payments climbed from $1.60 in 2013 to $6.56 in 2025 (2026 data is partial and excluded from this calculation). AbbVie Inc. dividend history shows the smallest annual increase in the window was 3.7% in 2014, while the largest single-year jump hit 40.2% in 2018. Eleven consecutive years of increases anchor that record, and a 12.5% CAGR is genuinely fast for a healthcare dividend payer.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +5.2% | $5.64 (2022) | $6.56 (2025) |
| 5-Year | +6.8% | $4.72 (2020) | $6.56 (2025) |
| 10-Year | +12.5% | $2.02 (2015) | $6.56 (2025) |
ABBV stock fits dividend investors who want above-average income growth from a healthcare business with broad therapeutic reach. The current yield of 2.58% is moderate (2–4%), and it sits above the 5-year average of 2.26%, which means buyers today are getting a slightly better entry yield than the historical norm. The trade-off is a payout ratio of 324.8%, which is far above what most income investors consider comfortable. What ABBV offers is a fast-growing dividend backed by a diversified drug portfolio. What it asks investors to accept is a payout structure that depends heavily on the company's ability to sustain revenue from key products rather than earnings coverage alone.
| Payment Date | Amount per Share |
|---|---|
| 2026-07-15 | $1.7300 |
| 2026-04-15 | $1.7300 |
| 2026-01-16 | $1.7300 |
| 2025-10-15 | $1.6400 |
| 2025-07-15 | $1.6400 |
| 2025-04-15 | $1.6400 |
| 2025-01-15 | $1.6400 |
| 2024-10-15 | $1.5500 |
| 2024-07-15 | $1.5500 |
| 2024-04-12 | $1.5500 |
| Year | Total Dividends |
|---|---|
| 2026 | $5.1900 |
| 2025 | $6.5600 |
| 2024 | $6.2000 |
| 2023 | $5.9200 |
| 2022 | $5.6400 |
Project income from ABBV with the ABBV dividend calculator or track your full portfolio with the dividend tracker.